"We applaud the actions of GSK, Alnylam, and other forward-thinking companies who want to contribute their knowledge and resources to help speed the development of medicines for poor patients in the developing world," says Moree. "The fact is that millions of people die each year from these neglected diseases and the pace of drug development is far too slow for the enormous need. The IP Pool will move medicines for neglected diseases forward more quickly and effectively and help save lives in the developing world."
About the Intellectual Property (IP) Pool
The diseases targeted by the pool are the 16 diseases identified by the FDA for its own Neglected Tropical Diseases initiative. These are tuberculosis, malaria, blinding trachoma, buruli ulcer, cholera, dengue/dengue haemorrhagic fever, racunculiasis, fascioliasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminthiasis and yaws. The geographic focus of the pool will be the world's Least Developed Countries as identified by the United Nations and includes much of western and central Africa as well as several countries in Southeast Asia.
About BIO Ventures for Global Health
BIO Ventures for Global Health is a non-profit organization whose mission is to save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world. The organization spurs biotech industr
|SOURCE BIO Ventures for Global Health|
Copyright©2010 PR Newswire.
All rights reserved